Cargando…

Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2

We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine steroid profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, George R, Beck, Katharina R, Patt, Melanie, Kratschmar, Denise V, Odermatt, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608555/
https://www.ncbi.nlm.nih.gov/pubmed/31286100
http://dx.doi.org/10.1210/js.2019-00189
_version_ 1783432189059268608
author Thompson, George R
Beck, Katharina R
Patt, Melanie
Kratschmar, Denise V
Odermatt, Alex
author_facet Thompson, George R
Beck, Katharina R
Patt, Melanie
Kratschmar, Denise V
Odermatt, Alex
author_sort Thompson, George R
collection PubMed
description We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine steroid profiles, revealed low renin and aldosterone and indicated as the underlying mechanism primarily a block of 11β-hydroxylase activity in patient 1, whereas patient 2 displayed weaker 11β-hydroxylase but more pronounced 11β-hydroxysteroid dehydrogenase 2 inhibition. The results show that both previously suggested mechanisms must be considered and emphasize significant interindividual differences in the contribution of each enzyme to the observed mineralocorticoid excess phenotype. The mineralocorticoid symptoms of patient 1 resolved after replacement of posaconazole therapy by isavoconazole, and posaconazole dosage de-escalation ameliorated the effects in patient 2. By providing a thorough analysis of the patients’ blood and urine steroid metabolites, this report adds further evidence for two individually pronounced mechanisms of posaconazole-induced hypertension and hypokalemia. The elucidation of the factors responsible for the individual phenotype warrants further research.
format Online
Article
Text
id pubmed-6608555
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-66085552019-07-08 Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 Thompson, George R Beck, Katharina R Patt, Melanie Kratschmar, Denise V Odermatt, Alex J Endocr Soc Case Report We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine steroid profiles, revealed low renin and aldosterone and indicated as the underlying mechanism primarily a block of 11β-hydroxylase activity in patient 1, whereas patient 2 displayed weaker 11β-hydroxylase but more pronounced 11β-hydroxysteroid dehydrogenase 2 inhibition. The results show that both previously suggested mechanisms must be considered and emphasize significant interindividual differences in the contribution of each enzyme to the observed mineralocorticoid excess phenotype. The mineralocorticoid symptoms of patient 1 resolved after replacement of posaconazole therapy by isavoconazole, and posaconazole dosage de-escalation ameliorated the effects in patient 2. By providing a thorough analysis of the patients’ blood and urine steroid metabolites, this report adds further evidence for two individually pronounced mechanisms of posaconazole-induced hypertension and hypokalemia. The elucidation of the factors responsible for the individual phenotype warrants further research. Endocrine Society 2019-06-06 /pmc/articles/PMC6608555/ /pubmed/31286100 http://dx.doi.org/10.1210/js.2019-00189 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Thompson, George R
Beck, Katharina R
Patt, Melanie
Kratschmar, Denise V
Odermatt, Alex
Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
title Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
title_full Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
title_fullStr Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
title_full_unstemmed Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
title_short Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
title_sort posaconazole-induced hypertension due to inhibition of 11β-hydroxylase and 11β-hydroxysteroid dehydrogenase 2
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608555/
https://www.ncbi.nlm.nih.gov/pubmed/31286100
http://dx.doi.org/10.1210/js.2019-00189
work_keys_str_mv AT thompsongeorger posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2
AT beckkatharinar posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2
AT pattmelanie posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2
AT kratschmardenisev posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2
AT odermattalex posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2